Showing results (221-230 of 691) with videos related to

Sort By:
Pageof 70
Journal of Neuro-Oncology|May 9, 2014
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumabRifaquat Rahman, Alhafidz Hamdan, Rebecca Zweifler, et al.
Neuro-Oncology|September 21, 2019
Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomasMaya Harary, Vasileios K Kavouridis, Matthew Torre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
The Misclassification of Diffuse Gliomas: Rates and OutcomesJ Bryan Iorgulescu, Matthew Torre, Maya Harary, et al.
The Oncologist|March 15, 2013
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studiesHerbert I Hurwitz, Pamela S Douglas, John P Middleton, et al.
Neuro-Oncology Practice|March 20, 2025
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?Marjolein Geurts, Luzia Berchtold, Franz Koenig, et al.
Cancer|July 4, 2013
Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumabRaymond Y Huang, Rifaquat Rahman, Alhafidz Hamdan, et al.
Investigational New Drugs|May 22, 2020
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant gliomaDavid A Reardon, Annick Desjardins, Olivier Rixe, et al.
European Radiology|September 22, 2021
Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosisClaudia E Weber, Julia Krämer, Matthias Wittayer, et al.
Stroke|June 10, 2020
Acute Stroke in Times of the COVID-19 Pandemic: A Multicenter StudyCarolin Hoyer, Anne Ebert, Hagen B Huttner, et al.
Stem Cells and Development|November 6, 2009
Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1)Tobias V Lanz, Christiane A Opitz, Peggy P Ho, et al.
Pageof 70